Antithrombotic Therapy After Coronary Artery Bypass Grafting Combined With Coronary Endarterectomy
Comparison of Antithrombotic Therapy After Coronary Artery Bypass Grafting Combined With Coronary Endarterectomy
China National Center for Cardiovascular Diseases
202 participants
Apr 11, 2023
INTERVENTIONAL
Conditions
Summary
Coronary endarterectomy (CE) combined with coronary artery bypass grafting (CABG) can be the final option for achieving complete revascularization in diffuse coronary artery disease patients. Since the exposure of subendothelial tissue to the blood flow after CE, the coagulation cascade can be activated, resulting in the increased risk of graft failure. Therefore, anticoagulation with warfarin in this group of patients might be beneficial. However, evidence is limited. This study aims to compare the clinical outcomes between dual antiplatelet therapy with or without warfarin after CE+CABG.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
dual antiplatelet therapy combined with warfarin
Dual antiplatelet therapy (aspirin plus either clopidogrel or ticagrelor)
Coronary endarterectomy combined with coronary artery bypass grafting
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05782270